Tag Archive for: Haematology

Poolbeg Pharma plc – Two posters with POLB 001 preclinical data presented at the European Hematology Association Congress

/in

Posters highlight POLB 001’s potential in CRS prevention and ability to enhance AML treatment in elderly patients, potentially expanding into a new indication  ·    First poster shows that POLB 001 decreased key CRS-associated cytokines and did not impair bispecific antibody-induced tumour cell death in a series of preclinical investigations ·    Second poster demonstrates the potential for POLB […]

Read more

Cycuria Therapeutics Launches with the Formation of a Distinguished Advisory Board and Significant Public Grant Funding

/in

Cycuria aims to revolutionise treatment of hard-to-treat blood cancers with a first-in-class protein-based therapeutic approach specifically targeting both tumour cells and tumour stem cells Advisory Board unites distinguished experts in corporate strategy, clinical haemato-oncology, protein engineering and early-stage drug discovery and development Grant funding secured from innovation-supporting Austrian government bodies FFG and AWS Graz, Austria, […]

Read more

Poolbeg Pharma plc to present POLB 001 pre-clinical study data at the 66th American Society of Hematology (ASH) Annual Meeting

/in

POLB 001 Reduces Cytokine Release Syndrome (CRS) in an in vivo animal model Positive results reinforce POLB 001’s potential in the prevention and treatment of cancer immunotherapy-induced CRS ASH is the world’s premier conference focussing on haematological malignancies 6 November 2024 – Poolbeg Pharma (AIM: POLB, ‘Poolbeg’ or the ‘Company’), a clinical-stage biopharmaceutical company focussed on the development […]

Read more

CellCentric to present inobrodib Phase I multiple myeloma efficacy and safety data at the American Society of Haematology

/in

Inobrodib is a pioneering drug targeting twin tumour drivers p300/CBP, providing a new way to treat specific cancers Objective responses have been observed in multiple settings, including as monotherapy in relapsed refractory multiple myeloma ASH is the annual flagship scientific and clinical haematology meeting which is taking place in New Orleans on 9-13 December 2022 […]

Read more
© Optimum Strategic Communications.